Gilead: Hep C Prescriptions Hold at 94% Among New Patients
March 04, 2016 at 11:07 AM EST
Citigroup’s Robyn Karnauskas and Mohit Bansal have the latest IMS prescription data for Gilead Sciences’ (GILD) hepatitis C treatments, with new starts falling slightly week over week but holding a 94% share among the new patients. We are in week #4 of new competition launch. However, new pt. starts are tracking 3% below last Q […]